Corrigendum to “The Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on “Profibrotic Cytokine” IL-1β Levels in Severe and Critical COVID-19 Patients: A Preliminary Study”

In the article “The Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on “Profibrotic Cytokine” IL-1β Levels in Severe and Critical COVID-19 Patients: A Preliminary Study” [1], the authors would like to update the Methods section as follows.

2. Methods

This interventional preliminary study recruited 12 patients of both sexes between the age of 18–65 years as interim data of Phase II clinical trials. The study protocol was ethically approved by the Health Research Ethics Committee, University of Indonesia, and Cipto Mangunkusumo Hospital (HREC-FMUI/CMH) and is registered on ClinicalTrials.gov (NCT04715360).